Table 2.
Comparison of the clinical characteristics between the NS-group and S-group
| S-group (n = 203) | NS-group (n = 404) | p-value | |
|---|---|---|---|
| Age over 65 years old, n (%) | 113 (55.9) | 224 (55.3) | 0.931 |
| Male Sex, n (%) | 110 (54.4) | 225 (55.8) | 0.667 |
| Steroids, n (%) | 5 (2.5) | 12 (3.0) | 0.801 |
| Diabetes Mellitus, n (%) | 37 (18.1) | 64 (15.8) | 0.489 |
| Alb (g/dl), Average ± SD | 3.5 ± 0.7 | 3.3 ± 0.8 | < 0.01* |
| CRP (mg/dl), Average ± SD | 1.7 ± 3.7 | 2.4 ± 4.5 | 0.0577 |
| Nutrition, n (%) | 40 (20.1) | 130 (32.3) | < 0.01* |
| ANC < 1500 cells/mm3, n (%) | 15 (7.4) | 21 (5.2) | 0.28 |
| Underlying Disease | |||
| Colon and Intestinal Cancer, n (%) | 65 (31.8) | 104 (25.7) | 0.125 |
| Head and Neck Cancer, n (%) | 5 (2.5) | 38 (9.4) | < 0.01* |
| Hepatobiliary Pancreatic Cancer, n (%) | 48 (23.6) | 111 (27.4) | 0.329 |
| Gastric Cancer, n (%) | 12 (5.9) | 20 (4.9) | 0.701 |
| Esophageal Cancer, n (%) | 13 (6.4) | 11 (2.7) | 0.0443* |
| Breast Cancer, n (%) | 4 (2.0) | 15 (3.7) | 0.326 |
| Gynecologic Cancer, n (%) | 19 (9.3) | 48 (12.1) | 0.411 |
| Hematological Disease, n (%) | 17 (8.3) | 12 (3.0) | 0.01* |
| Lung Cancer, n (%) | 12 (5.9) | 8 (2.0) | 0.0149* |
| Urothelial and Kidney Cancer, n (%) | 2 (1.0) | 5 (1.2) | 1 |
| Primary Brain Tumor, n (%) | 2 (1.0) | 5 (1.2) | 1 |
| Soft Tissue and Bone Malignancies, n (%) | 1 (0.5) | 3 (0.7) | 1 |
| Other Benign Disease, n (%) | 3 (1.5) | 24 (5.9) | 0.0113* |
| Procedure Details | |||
| Right Sided Implantation, n (%) | 190 (93.6) | 370 (92.3) | 0.33 |
| Length of Catheter (cm), Average ± SD | 18.6 ± 2.7 | 16.6 ± 3.3 | < 0.01* |
| Preoperative Antibiotics, n (%) | 65 (32.0) | 172 (42.6) | 0.0135* |
| TIVAP-related Infection | |||
| Infection Rate, n (%) | 6 (3.0) | 31 (7.7) | 0.0294* |
| Infection per 1000 Catheter-Days | 0.114 | 0.214 | |
SD Standard Deviation, Alb Albumin, CRP C-reactive protein, ANC Absolute neutrophil count, TIVAP Totally implantable venous access port
*Statistically significant